BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/15/2019 7:45:48 AM | Browse: 690 | Download: 961
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 49195
Country/Territory South Korea
Received
2019-05-20 06:29
Peer-Review Started
2019-05-23 09:47
To Make the First Decision
2019-08-01 00:01
Return for Revision
2019-08-20 00:39
Revised
2019-09-03 13:42
Second Decision
2019-09-12 10:23
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-09-13 04:54
Articles in Press
2019-09-13 04:54
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-10-24 12:09
Publish the Manuscript Online
2019-11-15 07:45
ISSN 1948-5204 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Cohort Study
Article Title Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer
Manuscript Source Unsolicited Manuscript
All Author List Se Jun Park, Hyunho Kim, Kabsoo Shin, Myung Ah Lee and Tae Ho Hong
ORCID
Author(s) ORCID Number
Se Jun Park http://orcid.org/0000-0001-5486-9818
Hyunho Kim http://orcid.org/0000-0003-1276-713X
Kabsoo Shin http://orcid.org/0000-0002-6709-0894
Myung Ah Lee http://orcid.org/0000-0002-1204-0574
Tae Ho Hong http://orcid.org/0000-0003-3864-8104
Funding Agency and Grant Number
Corresponding Author Myung Ah Lee, MD, PhD, Professor, Division of Medical Oncology, Department of Internal Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Korea, 222 Banpo-daero, Secho-gu, Seoul 16509, South Korea. angelamd@catholic.ac.kr
Key Words Pancreatic cancer; Gemcitabine-refractory; Capecitabine; S-1; Second-line treatment;
Core Tip To date, there is no standard regimen for patients with gemcitabine-refractory pancreatic cancer with poor performance status. In this study, we compared the efficacy and toxicity of capecitabine and S-1 for such patients. The median progression free survival was longer in the S-1 group than in the capecitabine group; however, there were no statistical differences in their overall survival. Among grade 3 or 4 toxicity, hand-foot syndrome was significantly more common in the capecitabine group than in the S-1 group. Thus, oral chemotherapy can be considered as a second-line treatment in gemcitabine-refractory pancreatic cancer patients with poor performance status.
Publish Date 2019-11-15 07:45
Citation Park SJ, Kim HH, Shin KS, Hong TH, Lee MA. Oral chemotherapy for second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer. World J Gastrointest Oncol 2019; 11(11): 1021-1030
URL https://www.wjgnet.com/1948-5204/full/v11/i11/1021.htm
DOI https://dx.doi.org/10.4251/wjgo.v11.i11.1021
Full Article (PDF) WJGO-11-1021.pdf
Full Article (Word) WJGO-11-1021.docx
STROBE Statement 49195-STROBE-Statement-revision.pdf
Manuscript File 49195-Review.docx
Answering Reviewers 49195-Answering reviewers.pdf
Audio Core Tip 49195-Audio core tip.mp3
Conflict-of-Interest Disclosure Form 49195-Conflict-of-interest statement.pdf
Copyright License Agreement 49195-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 49195-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 49195-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate 49195-Language certificate.pdf
Peer-review Report 49195-Peer-review(s).pdf
Scientific Misconduct Check 49195-Scientific misconduct check.pdf
Scientific Editor Work List 49195-Scientific editor work list.pdf